by Sodium phenylbutyrate is a prodrug that helps break down ammonia levels in the body. It is widely used to treat urea cycle disorders (UCDs), a group of rare genetic disorders that affect the body’s ability to remove ammonia from the bloodstream. UCDs can be potentially life-threatening if not treated properly. With increasing awareness about UCDs and growing diagnosis of these disorders, the demand for sodium phenylbutyrate is expected to rise significantly in the coming years.
The global sodium phenylbutyrate market is estimated to be valued at US$ 2.22 Bn in 2024 and is expected to exhibit a CAGR of 18. % over the forecast period 2024 to 2031.
Sodium phenylbutyrate helps eliminate waste from the body and is prescribed to patients suffering from urea cycle disorders which inhibit the liver from breaking down toxic ammonia. It is available in various forms like tablets, capsules and powder for oral administration.
Key Takeaways
Key players operating in the sodium phenylbutyrate market are Halliburton Co., Hifi Engineering Inc., Silixa Ltd., Schlumberger Limited, Banweaver, Omnisens SA, Future Fibre Technologies Ltd., Baker Hughes, Inc., Qintiq Group PLC, and Fotech Solutions Ltd. The market provides significant opportunities for growth owing to increasing research on developing more potent formulations. Major companies are expanding their geographical presence in regions with high prevalence of UCDs such as North America and Europe.
Key opportunities in the market include new product launches with improved formulations and potency. Companies are increasingly investing in R&D to develop sodium phenylbutyrate formulations with better taste and ease of administration to improve patient compliance. The market is also witnessing a growing trend of global expansion with companies entering emerging markets of Asia Pacific and Latin America.
Market drivers
The key driver propelling the growth of Sodium Phenylbutyrate Market Size is increasing incidences of urea cycle disorders. UCDs have a low prevalence rate but the diagnosis of these rare genetic disorders has increased over the years due to availability of advanced screening and diagnostic tests. Rising awareness among patients and healthcare professionals about available treatment options for UCDs like sodium phenylbutyrate therapy has also boosted the market growth. Furthermore, growing geriatric population prone to metabolic disorders and expanding applications of sodium phenylbutyrate in other therapeutic areas are expected to drive the market during the forecast period.
PEST Analysis
Political: Regulations regarding the manufacturing and marketing of pharmaceutical products are quite stringent. Any changes in regulatory policies can affect the sodium phenylbutyrate market.
Economic: Growing healthcare expenditure worldwide is fueling the demand for orphan drugs like sodium phenylbutyrate which is used for treating rare urea cycle disorders.
Social: Increasing awareness about rare diseases and availability of treatment options is driving more patients to opt for sodium phenylbutyrate therapy.
Technological: Manufacturers are focusing on developing new drug delivery systems like extended-release formulations to improve patient compliance in sodium phenylbutyrate therapy.
Geographical concentration
North America dominates the global sodium phenylbutyrate market in terms of value owing to the strong healthcare infrastructure and high adoption of orphan drugs in the region. The US contributes substantially to the North America market led by the presence of major manufacturers and availability of favorable reimbursement policies.
Fastest growing region
Asia Pacific is expected to witness the fastest growth during the forecast period. Improving healthcare systems, rising healthcare spending, increasing incidences of rare diseases, and expanding patient access to advanced treatment options are some key factors fueling the sodium phenylbutyrate market in the Asia Pacific region. China and India are projected to drive the growth of the market in Asia Pacific.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
